US20100222591A1 - New Compounds - Google Patents
New Compounds Download PDFInfo
- Publication number
- US20100222591A1 US20100222591A1 US12/551,828 US55182809A US2010222591A1 US 20100222591 A1 US20100222591 A1 US 20100222591A1 US 55182809 A US55182809 A US 55182809A US 2010222591 A1 US2010222591 A1 US 2010222591A1
- Authority
- US
- United States
- Prior art keywords
- methoxy
- methyl
- benzimidazole
- sulfinyl
- pyridinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- SUBDBMMJDZJVOS-UHFFFAOYSA-N COC1=CC2=C(C=C1)NC(S(=O)CC1=NC=C(C)C(OC)=C1C)=N2.[Na+] Chemical compound COC1=CC2=C(C=C1)NC(S(=O)CC1=NC=C(C)C(OC)=C1C)=N2.[Na+] SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- OSVOTHKJGLURMH-UHFFFAOYSA-N CCN1C(S(=O)CC2=NC=C(C)C(OC)=C2C)=NC2=C1C=CC=C2.COC Chemical compound CCN1C(S(=O)CC2=NC=C(C)C(OC)=C2C)=NC2=C1C=CC=C2.COC OSVOTHKJGLURMH-UHFFFAOYSA-N 0.000 description 1
- NHJWXNNCIQJHPV-UHFFFAOYSA-N COC1=CC2=C(C=C1)N=C(S(=O)CC1=NC=C(C)C(OC)=C1C)N2COC(=O)C(O)C1=CC=CC=C1 Chemical compound COC1=CC2=C(C=C1)N=C(S(=O)CC1=NC=C(C)C(OC)=C1C)N2COC(=O)C(O)C1=CC=CC=C1 NHJWXNNCIQJHPV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention is directed to new compounds of high optical purity and crystalline salts thereof, their use in medicine, a process for their preparation and their use in the manufacture of pharmaceutical preparation.
- the invention also relates to novel intermediates in the preparation of the compounds of the invention.
- the present invention provides such compounds, which are novel salts of single enantiomers of omeprazole.
- a preferred embodiment of the present invention provides pure crystalline enantiomeric salts of omeprazole and methods for the preparation thereof.
- a more preferred embodiment of the present invention is directed to an optically pure crystalline enantiomeric magnesium salt of omeprazole and method for the preparation thereof.
- a nonaqueous process according to the present invention is directed to the preparation of crystalline forms of an optically pure enantiomer of omeprazole magnesium salt or analogues thereof which includes steps of stirring a crude preparation of the omeprazole enantiomer under nitrogen into a methanolic magnesium methoxide solution, precipitating inorganic magnesium salt with addition of a small amount of water, removing any precipitated inorganic magnesium salts, concentrating the residual methanolic solution, precipitating the omeprazole enantiomer by adding acetone to the residual solution, and filtering off the optically pure enantiomer crystals of magnesium omeprazole or analogues thereof.
- the present invention in a further aspect provides a novel method for preparing the novel compounds of the invention in large scale.
- This novel method can also be used in large scale to obtain single enantiomers of omeprazole in neutral form.
- the compounds according to the invention may be used for inhibiting gastric acid secretion in mammals and man.
- the compounds of the invention may be used for the treatment of gastric acid-related diseases and gastrointestinal inflammatory diseases in mammals and man, such as gastric ulcer, duodenal ulcer, reflux esophagitis, and gastritis.
- the compounds may be used for treatment of other gastrointestinal disorders where gastric antisecretory effect is desirable e.g. in patients on NSAID therapy, in patients with gastrinomas, and in patients with acute upper gastrointestinal bleeding. They may also be used in patients in intensive care situations, and pre- and postoperatively to prevent acid aspiration and stress ulceration.
- the compound of the invention may also be used for treatment or prophylaxis of inflammatory conditions in mammals, including man, especially those involving lysozymal enzymes. Conditions that may be specifically mentioned for treatment are rheumatoid arthritis and gout.
- the compound of the invention may also be useful in the treatment of psoriasis as well as in the treatment of Helicobacter infections.
- the present invention refers to the new Na + , Mg 2+ , Li + , K + , Ca 2+ and N + (R) 4 salts of the single enantiomers of omeprazole, where R is an alkyl with 1-4 carbon atoms, i.e.
- Particularly preferred salts according to the invention are the Na + , Ca 2+ and Mg 2+ salts, i.e (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt, ( ⁇ )-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt, (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole magnesium salt, ( ⁇ )-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole magnesium salt, (+)-5-methoxy-2-[[(4-
- salts according to the invention are the optically pure Na + salts of omeprazole according to compounds Ia and Ib
- optically pure Na + salts of omeprazole is meant the (+)-enantiomer of omeprazole Na-salt essentially free of the ( ⁇ )-enantiomer of omeprazole Na-salt and the ( ⁇ )-enantiomer essentially free of the (+)-enantiomer, respectively.
- Single enantiomers of omeprazole have hitherto only been obtained as syrups and not as crystalline products.
- the salts defined by the present invention are easy to obtain by means of the novel specific method according to one aspect of the invention of preparing the single enantiomers of omeprazole. In contrast to the neutral forms the salts can be obtained as crystalline products.
- optically impure or partially pure salts of the enantiomers of omeprazole can be obtained in very high optical purity, namely ⁇ 99.8% enantiomeric excess (e.e.) even from an optically contaminated preparation.
- the optically pure salts are stable resisting racemization both in neutral pH and basic pH, which is surprising since the known deprotonation at the carbon atom between the pyridine ring and the chiral sulfur atom was expected to cause racemization under alkaline conditions. This high stability against racemization makes it possible to use a single enantiomeric salt of the invention in therapy.
- the specific method of preparation of the single enantiomers of omeprazole is a further aspect of the invention as mentioned above and it can be used to obtain the single enantiomers of omeprazole in neutral form as well as the salts thereof.
- Yet a further aspect of the invention is the compound III, which is an intermediate used in the specific method of preparation.
- optically pure compounds of the invention i.e. the single enantiomers
- the optically pure compounds of the invention are prepared by separating the two stereoisomers of a diastereomeric mixture of the following type, 5- or 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1-[acyloxymethyl]-1H-benzimidazole, formula IV
- the Acyl moiety in the diastereomeric ester may be a chiral acyl group such as mandeloyl, and the asymmetric center in the chiral acyl group can have either R or S configuration.
- the diastereomeric esters can be separated either by chromatography or fractional crystallization.
- the solvolysis usually takes place together with a base in a protic solvent such as alcohols or water, but the acyl group may also be hydrolyzed off by a base in an aprotic solvent such as dimethylsulfoxide or dimethylformamide.
- the reacting base may be OH ⁇ or R 1 O ⁇ where R 1 can be any alkyl or aryl group.
- the resulting compound is treated with a base, such as NaOH, in an aqueous or nonaqueous medium, or with NaOR 2 wherein R 2 is an alkyl group containing 1-4 carbon atoms, or with NaNH 2 .
- a base such as NaOH
- NaOR 2 wherein R 2 is an alkyl group containing 1-4 carbon atoms
- NaNH 2 alkaline salts wherein the cation is Li + or K + may be prepared using lithium or potassium salts of the above mentioned bases.
- addition of NaOH in a non-aqueous medium such as a mixture of 2-butanone and toluene, is preferred.
- optically pure enantiomeric Na + salts may be treated with an aqueous solution of an inorganic magnesium salt such as MgCl 2 , whereupon the Mg 2+ salts are precipitated.
- the optically pure Mg 2+ salts may also be prepared by treating single enantiomers of omeprazole with a base, such as Mg(OR 3 ) 2 , wherein R 3 is an alkyl group containing 1-4 carbon atoms, in a non-aqueous solvent such as alcohol (only for alcoholates), e.g. ROH, or in an ether such as tetrahydrofuran.
- a base such as Mg(OR 3 ) 2 , wherein R 3 is an alkyl group containing 1-4 carbon atoms
- a non-aqueous solvent such as alcohol (only for alcoholates), e.g. ROH, or in an ether such as tetrahydrofuran.
- Alkaline salts of the single enantiomers of the invention are, as mentioned above, beside the sodium salts (compounds Ia and Ib) and the magnesium salts (compounds IIa and IIb), exemplified by their salts with Li + , K + , Ca 2+ and N + (R) 4 , where R is an alkyl with 1-4 C-atoms.
- the single enantiomers, i.e. the optically pure compounds, of the invention are formulated into pharmaceutical formulations for oral, rectal, parenteral or other modes of administrations.
- the pharmaceutical formulations contain the single enantiomers of the invention normally in combination with a pharmaceutically acceptable carrier.
- the carrier may be in form of a solid, semi-solid or liquid diluent, or capsule.
- These pharmaceutical preparations are a further object of the invention.
- the amount of active compound is between 0.1-95% by weight of the preparation, between 0.2-20% by weight in preparations for parenteral use and between 1-50% by weight in preparations for oral administration.
- the optically pure compound may be mixed with a solid, powdered carrier, such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivates, gelatin or another suitable carrier, stabilizing substances such as alkaline compounds e.g. carbonates, hydroxides and oxides of sodium, potassium, calcium, magnesium and the like as well as with lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethyleneglycol waxes.
- a solid, powdered carrier such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivates, gelatin or another suitable carrier
- stabilizing substances such as alkaline compounds e.g. carbonates, hydroxides and oxides of sodium, potassium, calcium, magnesium and the like as well as with lubricating agents such as magnesium stearate, calcium stearate, sodium
- Granules and tablets may be coated with an enteric coating which protects the active compound from acid catalyzed degradation as long as the dosage form remains in the stomach.
- the enteric coating is chosen among pharmaceutically acceptable enteric-coating materials e.g. beeswax, shellac or anionic film-forming polymers and the like, if preferred in combination with a suitable plasticizer.
- enteric-coating materials e.g. beeswax, shellac or anionic film-forming polymers and the like, if preferred in combination with a suitable plasticizer.
- To the coating various dyes may be added in order to distinguish among tablets or granules with different amounts of the active compound present.
- Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules. Soft gelatine capsules may also be enteric-coated as described above.
- Hard gelatine capsules may contain granules or enteric-coated granules of the active compound. Hard gelatine capsules may also contain the active compound in combination with a solid powdered carrier such as lactose, saccharose, sorbitol, mannitol, potato starch, amylopectin, cellulose derivates or gelatin. The capsules may be enteric-coated as described above.
- Dosage units for rectal administration may be prepared in the form of suppositories which contain the active substance mixed with a neutral fat base, or they may be prepared in the form of a gelatine rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil or other suitable vehicle for gelatine rectal capsules, or they may be prepared in the form of a ready-made micro enema, or they may be prepared in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.
- Liquid preparation for oral administration may be prepared in the form of syrups or suspensions, e.g. solutions or suspensions containing from 0.2% to 20% by weight of the active ingredient and the remainder consisting of sugar or sugar alcohols and a mixture of ethanol, water, glycerol, propylene glycol and/or polyethylene glycol. If desired, such liquid preparations may contain coloring agents, flavoring agents, saccharine and carboxymethyl cellulose or other thickening agents. Liquid preparations for oral administration may also be prepared in the form of dry powder to be reconstituted with a suitable solvent prior to use.
- Solutions for parenteral administrations may be prepared as solutions of the optically pure compounds of the invention in pharmaceutically acceptable solvents, preferably in a concentration from 0.1 to 10% by weight. These solutions may also contain stabilizing agents and/or buffering agents and may be manufactured in different unit dose ampoules or vials. Solutions for parenteral administration may also be prepared as dry preparations to be reconstituted with a suitable solvent extemporaneously before use.
- the typical daily dose of the active compound will depend on various factors such as for example the individual requirement of each patient, the route of administration and the disease. In general, oral and parenteral dosages will be in the range of 5 to 500 mg per day of active substance.
- the invention is illustrated by the following examples using preferred procedures for the preparation of optically pure sodium salts and magnesium salts.
- (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H-benzimidazole sodium salt (0.165 g, 0.45 mmol) was dissolved in water (3 ml).
- To this mixture 2 ml of an aqueous solution of MgCl 2 xH 2 O (46 mg, 0.23 mmol) was added dropwise and the formed precipitate was isolated by centrifugation. There was obtained 85 mg (51%) of the product as a white powder.
- the optical purity (ee) of the product was 99.9% which was the same or better as the optical purity of the starting material.
- the crystalline salt according to Example 6 is most preferred.
- Example 8 The diastereomers of the title compound in Example 8 were separated using reversed phase chromatography (HPLC). Approximately 300 mg of the diastereomeric mixture was dissolved in 10 ml hot acetonitrile which was diluted with 10 ml of a mixture of aqueous 0.1 M ammoniumacetate and acetonitrile (70/30). The solution was injected to the column and the compounds were eluted with a mixture of aqueous 0.1 M ammoniumacetate and acetonitrile (70/30). The more hydrophilic isomer was easier to obtain pure than the less hydrophilic one.
- HPLC reversed phase chromatography
- the product was obtained from 8.1 g (202 mmol) sodium hydroxide in 100 ml water, 34.4 g (101 mmol) tetrabutylammonium hydrogen sulfate, 15.4 g (101 mmol) (S)-(+)-mandelic acid and 39.9 g (101 mmol) of the racemate of 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1-[chloromethyl]-1H-benzimidazole using the same procedure as in Example 8. Recrystallization from 100 ml acetonitrile yielded 21.3 g, i.e. 41% of the title compound as a diastereomeric mixture.
- Example 10 The diastereomers of the title compound in Example 10 were separated using reversed phase chromatography (HPLC) in the same way as in Example 7, but using the diasteromeric mixture of 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-(R/S)-sulfinyl]-1-[(S)-mandeloloxymethyl]-1H-benzimidazole instead of the (R)-mandelic ester used in Example 9. Using 2.1 g of the diastereomeric mixture, the more hydrophilic isomer, 760 mg, was obtained in a pure state as a colorless syrup.
- CDCl 3 2.18, (s, 3H), 2.22 (s, 3H), 3.68 (s, 3H), 3.83 (s, 3H), 300 MHz 4.77 (m, 2H), 6.93 (dd, 1H), ⁇ 7.0 (b, 1H), ⁇ 7.5 (b, 1H), 8.19 (s, 1H). 13. CDCl 3 2.21 (s, 3H), 2.23 (s, 3H), 3.69 (s, 3H), 3.84 (s, 3H), 4.76 (m, 2H), 6.94 (dd, 1H), ⁇ 7.0 (b, 1H), ⁇ 7.5 (b, 1H), 8.20 (s, 1H).
- compositions containing the compounds of the invention as active ingredient are illustrated in the following formulations.
- a syrup containing 1% (weight per volume) of active substance was prepared from the following ingredients:
- An enteric coated tablet containing 50 mg of active compound was prepared from the following ingredients:
- the dry mixture was pressed into tablet cores (10 000 tablets), each tablet containing 50 mg of active substance, in a tabletting machine using 7 mm diameter punches.
- a solution of cellulose acetate phthalate and cetyl alcohol in isopropanol/methylene chloride was sprayed onto the tablets I in an Accela Cota®, Manesty coating equipment. A final tablet weight of 110 mg was obtained.
- a parenteral formulation for intravenous use containing 4 mg of active compound per ml, was prepared from the following ingredients:
- the active compound was dissolved in water to a final volume of 1000 ml.
- the solution was filtered through a 0.22 ⁇ m filter and immediately dispensed into 10 ml sterile ampoules. The ampoules were sealed.
- Capsules containing 30 mg of active compound were prepared from the following ingredients:
- the active compound was mixed with the dry ingredients and granulated with a solution of disodium hydrogen phosphate.
- the wet mass was forced through an extruder and spheronized and dried in a fluidized bed dryer.
- Hydroxypropyl methylcellulose phthalate 70 g Cetyl alcohol 4 g Acetone 200 g Ethanol 600 g
- the final coated pellets were filled into capsules.
- Suppositories were prepared from the following ingredients using a welding procedure. Each suppository contained 40 mg of active compound.
- the active compound was homogenously mixed with Witepsol H-15 at a temperature of 41° C.
- the molten mass was volume filled into pre-fabricated suppository packages to a net weight of 1.84 g. After cooling the packages were heat sealed.
- Each suppository contained 40 mg of active compound.
- the stability of the optically pure compounds of the invention against racemization has been measured at low concentrations in a refrigerator in aqueous buffer solutions at pH 8, 9.3, 10 and 11.2.
- the stereochemical stability was measured by comparing the optical purity for the ( ⁇ )-isomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole in buffer solution immediately after dissolving and after several days.
- the measurement was performed by chromatography on an analytical chiral column.
- the surprising high stereochemical stability in alkaline conditions for the compounds of invention is exemplified by the fact that no racemization for the test compound was obtained at pH 11.2 even after 21 days. At pH 8, 9.3 and 10, the chemical degradation of the compound is more apparent which makes the racemization measurement more difficult to perform, however at none of these pH values a detectable racemization was obtained after 16 days.
Abstract
The novel optically pure compounds Na+, Mg2+, Li+, K+, Ca2+ and N+(R)4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.
Description
- This application is a continuation-in-part of copending Ser. No. 08/256,174.
- The present invention is directed to new compounds of high optical purity and crystalline salts thereof, their use in medicine, a process for their preparation and their use in the manufacture of pharmaceutical preparation. The invention also relates to novel intermediates in the preparation of the compounds of the invention.
- The compound 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, having the generic name omeprazole, and therapeutically acceptable alkaline salts thereof are described in U.S. Pat. No. 4,255,431 to Junggren et al., EP 5129 and EP 124 495, respectively. Omeprazole and its alkaline salts are effective gastric acid secretion inhibitors, and are useful as antiulcer agents. The compounds, being sulfoxides, have an asymmetric center in the sulfur atom, i.e. exist as two optical isomers (enantiomers).
- The separation of the enantiomers of omeprazole in analytical scale is described in e.g. J. Chromatography, 532 (1990), 305-19 and in a preparative scale in DE 4035455. The latter has been done by using a diastereomeric ether which is separated and thereafter hydrolysed in an acidic solution. Under the acidic conditions needed for hydrolysis of the attached group, omeprazole is quite sensitive and the acid has to be quickly neutralized with a base to avoid degradation of the acid-sensitive compound. In the above mentioned application (DE 4035455) this is done by adding the reaction mixture containing concentrated sulfuric acid to a concentrated solution of NaOH. This is disadvantageous because there is a great risk of locally reaching pH values between 1-6, which would be devastating for the substance. Moreover, instantaneous neutralization will create heat which will be difficult to handle in large scale production.
- There is no example in the known prior art of any isolated or characterized salt of optically pure omeprazole, i.e. of single enantiomers of omeprazole or of any isolated or characterized salt of any optically pure omeprazole analogue.
- It is desirable to obtain compounds with improved pharmacokinetic and metabolic properties which will give an improved therapeutic profile such as a lower degree of interindividual variation. The present invention provides such compounds, which are novel salts of single enantiomers of omeprazole.
- A preferred embodiment of the present invention provides pure crystalline enantiomeric salts of omeprazole and methods for the preparation thereof.
- A more preferred embodiment of the present invention is directed to an optically pure crystalline enantiomeric magnesium salt of omeprazole and method for the preparation thereof.
- A nonaqueous process according to the present invention is directed to the preparation of crystalline forms of an optically pure enantiomer of omeprazole magnesium salt or analogues thereof which includes steps of stirring a crude preparation of the omeprazole enantiomer under nitrogen into a methanolic magnesium methoxide solution, precipitating inorganic magnesium salt with addition of a small amount of water, removing any precipitated inorganic magnesium salts, concentrating the residual methanolic solution, precipitating the omeprazole enantiomer by adding acetone to the residual solution, and filtering off the optically pure enantiomer crystals of magnesium omeprazole or analogues thereof.
- The present invention in a further aspect provides a novel method for preparing the novel compounds of the invention in large scale. This novel method can also be used in large scale to obtain single enantiomers of omeprazole in neutral form.
- The compounds according to the invention may be used for inhibiting gastric acid secretion in mammals and man. In a more general sense, the compounds of the invention may be used for the treatment of gastric acid-related diseases and gastrointestinal inflammatory diseases in mammals and man, such as gastric ulcer, duodenal ulcer, reflux esophagitis, and gastritis. Furthermore, the compounds may be used for treatment of other gastrointestinal disorders where gastric antisecretory effect is desirable e.g. in patients on NSAID therapy, in patients with gastrinomas, and in patients with acute upper gastrointestinal bleeding. They may also be used in patients in intensive care situations, and pre- and postoperatively to prevent acid aspiration and stress ulceration. The compound of the invention may also be used for treatment or prophylaxis of inflammatory conditions in mammals, including man, especially those involving lysozymal enzymes. Conditions that may be specifically mentioned for treatment are rheumatoid arthritis and gout. The compound of the invention may also be useful in the treatment of psoriasis as well as in the treatment of Helicobacter infections.
- The present invention refers to the new Na+, Mg2+, Li+, K+, Ca2+ and N+(R)4 salts of the single enantiomers of omeprazole, where R is an alkyl with 1-4 carbon atoms, i.e. Na+, Mg2+, Li+, K+, Ca2+ and N+(R)4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, where R is an alkyl with 1-4 carbon atoms.
- Particularly preferred salts according to the invention are the Na+, Ca2+ and Mg2+ salts, i.e (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt, (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt, (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole magnesium salt, (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole magnesium salt, (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole calcium salt and (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole calcium salt.
- Most preferred salts according to the invention are the optically pure Na+ salts of omeprazole according to compounds Ia and Ib
- and the optically pure magnesium salts of omeprazole according to compounds IIa and IIb
- With the expression “optically pure Na+ salts of omeprazole” is meant the (+)-enantiomer of omeprazole Na-salt essentially free of the (−)-enantiomer of omeprazole Na-salt and the (−)-enantiomer essentially free of the (+)-enantiomer, respectively. Single enantiomers of omeprazole have hitherto only been obtained as syrups and not as crystalline products. The salts defined by the present invention are easy to obtain by means of the novel specific method according to one aspect of the invention of preparing the single enantiomers of omeprazole. In contrast to the neutral forms the salts can be obtained as crystalline products. Because it is possible to purify optically impure or partially pure salts of the enantiomers of omeprazole by crystallization, they can be obtained in very high optical purity, namely ≧99.8% enantiomeric excess (e.e.) even from an optically contaminated preparation. Moreover, the optically pure salts are stable resisting racemization both in neutral pH and basic pH, which is surprising since the known deprotonation at the carbon atom between the pyridine ring and the chiral sulfur atom was expected to cause racemization under alkaline conditions. This high stability against racemization makes it possible to use a single enantiomeric salt of the invention in therapy.
- The specific method of preparation of the single enantiomers of omeprazole is a further aspect of the invention as mentioned above and it can be used to obtain the single enantiomers of omeprazole in neutral form as well as the salts thereof.
- Yet a further aspect of the invention is the compound III, which is an intermediate used in the specific method of preparation.
- The optically pure compounds of the invention, i.e. the single enantiomers, are prepared by separating the two stereoisomers of a diastereomeric mixture of the following type, 5- or 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1-[acyloxymethyl]-1H-benzimidazole, formula IV
- wherein the methoxy substituent in the benzimidazole moiety is in position 5 or 6, and wherein the Acyl radical is as defined below, followed by a solvolysis of each separated diastereomer in an alkaline solution. The formed single enantiomers of omeprazole are then isolated by neutralizing aqueous solutions of the salts of the single enantiomers of omeprazole with a neutralizing agent which can be an acid or an ester such as methyl formate.
- The Acyl moiety in the diastereomeric ester may be a chiral acyl group such as mandeloyl, and the asymmetric center in the chiral acyl group can have either R or S configuration.
- The diastereomeric esters can be separated either by chromatography or fractional crystallization.
- The solvolysis usually takes place together with a base in a protic solvent such as alcohols or water, but the acyl group may also be hydrolyzed off by a base in an aprotic solvent such as dimethylsulfoxide or dimethylformamide. The reacting base may be OH− or R1O− where R1 can be any alkyl or aryl group.
- To obtain the optically pure Na+ salts of the invention, i.e. the single enantiomers of omeprazole Na+ salts, the resulting compound is treated with a base, such as NaOH, in an aqueous or nonaqueous medium, or with NaOR2 wherein R2 is an alkyl group containing 1-4 carbon atoms, or with NaNH2. In addition, alkaline salts wherein the cation is Li+ or K+ may be prepared using lithium or potassium salts of the above mentioned bases. In order to obtain the crystalline form of the Na+ salt, addition of NaOH in a non-aqueous medium such as a mixture of 2-butanone and toluene, is preferred.
- To obtain the optically pure Mg2+ salts of the invention, optically pure enantiomeric Na+ salts may be treated with an aqueous solution of an inorganic magnesium salt such as MgCl2, whereupon the Mg2+ salts are precipitated. The optically pure Mg2+ salts may also be prepared by treating single enantiomers of omeprazole with a base, such as Mg(OR3)2, wherein R3 is an alkyl group containing 1-4 carbon atoms, in a non-aqueous solvent such as alcohol (only for alcoholates), e.g. ROH, or in an ether such as tetrahydrofuran. In an analogous way, also alkaline salts wherein the cation is Ca2+ can be prepared, using an aqueous solution of an inorganic calcium salt such as CaCl2.
- Alkaline salts of the single enantiomers of the invention are, as mentioned above, beside the sodium salts (compounds Ia and Ib) and the magnesium salts (compounds IIa and IIb), exemplified by their salts with Li+, K+, Ca2+ and N+(R)4, where R is an alkyl with 1-4 C-atoms.
- For clinical use the single enantiomers, i.e. the optically pure compounds, of the invention are formulated into pharmaceutical formulations for oral, rectal, parenteral or other modes of administrations. The pharmaceutical formulations contain the single enantiomers of the invention normally in combination with a pharmaceutically acceptable carrier. The carrier may be in form of a solid, semi-solid or liquid diluent, or capsule. These pharmaceutical preparations are a further object of the invention. Usually the amount of active compound is between 0.1-95% by weight of the preparation, between 0.2-20% by weight in preparations for parenteral use and between 1-50% by weight in preparations for oral administration.
- In the preparation of pharmaceutical formulations in form of dosage units for oral administration the optically pure compound may be mixed with a solid, powdered carrier, such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivates, gelatin or another suitable carrier, stabilizing substances such as alkaline compounds e.g. carbonates, hydroxides and oxides of sodium, potassium, calcium, magnesium and the like as well as with lubricating agents such as magnesium stearate, calcium stearate, sodium stearyl fumarate and polyethyleneglycol waxes. The mixture is then processed into granules or pressed into tablets. Granules and tablets may be coated with an enteric coating which protects the active compound from acid catalyzed degradation as long as the dosage form remains in the stomach. The enteric coating is chosen among pharmaceutically acceptable enteric-coating materials e.g. beeswax, shellac or anionic film-forming polymers and the like, if preferred in combination with a suitable plasticizer. To the coating various dyes may be added in order to distinguish among tablets or granules with different amounts of the active compound present.
- Soft gelatine capsules may be prepared with capsules containing a mixture of the active compound, vegetable oil, fat, or other suitable vehicle for soft gelatine capsules. Soft gelatine capsules may also be enteric-coated as described above.
- Hard gelatine capsules may contain granules or enteric-coated granules of the active compound. Hard gelatine capsules may also contain the active compound in combination with a solid powdered carrier such as lactose, saccharose, sorbitol, mannitol, potato starch, amylopectin, cellulose derivates or gelatin. The capsules may be enteric-coated as described above.
- Dosage units for rectal administration may be prepared in the form of suppositories which contain the active substance mixed with a neutral fat base, or they may be prepared in the form of a gelatine rectal capsule which contains the active substance in a mixture with a vegetable oil, paraffin oil or other suitable vehicle for gelatine rectal capsules, or they may be prepared in the form of a ready-made micro enema, or they may be prepared in the form of a dry micro enema formulation to be reconstituted in a suitable solvent just prior to administration.
- Liquid preparation for oral administration may be prepared in the form of syrups or suspensions, e.g. solutions or suspensions containing from 0.2% to 20% by weight of the active ingredient and the remainder consisting of sugar or sugar alcohols and a mixture of ethanol, water, glycerol, propylene glycol and/or polyethylene glycol. If desired, such liquid preparations may contain coloring agents, flavoring agents, saccharine and carboxymethyl cellulose or other thickening agents. Liquid preparations for oral administration may also be prepared in the form of dry powder to be reconstituted with a suitable solvent prior to use.
- Solutions for parenteral administrations may be prepared as solutions of the optically pure compounds of the invention in pharmaceutically acceptable solvents, preferably in a concentration from 0.1 to 10% by weight. These solutions may also contain stabilizing agents and/or buffering agents and may be manufactured in different unit dose ampoules or vials. Solutions for parenteral administration may also be prepared as dry preparations to be reconstituted with a suitable solvent extemporaneously before use.
- The typical daily dose of the active compound will depend on various factors such as for example the individual requirement of each patient, the route of administration and the disease. In general, oral and parenteral dosages will be in the range of 5 to 500 mg per day of active substance.
- The invention is illustrated by the following examples using preferred procedures for the preparation of optically pure sodium salts and magnesium salts.
- The processes described below for optically pure enantiomeric sodium salts of omeprazole result in change of directions from (−) to (+) optical rotation and, vice versa, from (+) to (−) optical rotation when preparing the sodium salt from the neutral form of omeprazole and again, when preparing the magnesium salt from the sodium salt of omeprazole.
- 100 mg (0.3 mmol) of (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole (contaminated with 3% of the (+)-isomer) was dissolved in 1 ml of 2-butanone with stirring. 60 μl of an aqueous solution of 5.0M sodium hydroxide and 2 ml of toluene were added. The resultant mixture was non-homogeneous. In order to obtain a clear solution, more 2-butanone was added (ca 1 ml) and the mixture was stirred at ambient temperature over night. The formed precipitate was filtered off and washed with ether. There was obtained 51 mg (46%) of the title compound as white crystals m.p. (decomposition) 246-248° C. The optical purity (e.e.) which was analyzed by chiral column chromatography was ≧99.8%. [α]D 20=+42.8° (concentration, c=0.5%, water).
- NMR data are given below.
- 100 mg-(0.3 mmol) of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole (contaminated with 3% of the (−)-isomer) was dissolved in 1 ml of 2-butanone with stirring. 60 μl of an aqueous solution of 5.0 M sodium hydroxide and 2 ml of toluene were added. The resultant mixture was non-homogeneous. In order to obtain a clear solution, more 2-butanone was added (ca 1 ml) and the mixture was stirred at ambient temperature over night. The formed precipitate was filtered off and washed with ether. There was obtained 56 mg (51%) of the title compound as white crystals m.p. (decomposition) 247-249° C. The optical purity (e.e.) which was analyzed by chiral column chromatography was ≧99.8%. [α]D 20=−44.1° (c=0.5%, water).
- NMR data are given below.
- 2.9 ml of a 0.1 M solution of NaOH was added to 0.10 g (0.29 mmol) (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole. To this mixture 2 ml methylene chloride was added, and after mixing in a separatory funnel the aqueous solution was separated off. A solution of 14 mg (0.145 mmol) MgCl2 in water was added dropwise. The formed precipitate was isolated by centrifugation, and 52 mg (50%) of the product was isolated as an amorphous powder. The optical purity (e.e.) was 98%, and thus the same as the starting material. The optical purity was determined by chromatography on an analytical chiral column. [α]D 20=+101.2° (c=1%, methanol). The Mg content of the sample was found to be 3.0%, shown by atomic absorption spectroscopy.
- (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt (0.500 g, 1.36 mmol) was dissolved in water (10 ml). To this mixture 10 ml of an aqueous solution of MgCl2xH2O (138 mg, 0.68 mmol) was added dropwise and the formed precipitate was isolated by centrifugation. There was obtained 418 mg (86%) of the product as a white powder. The optical purity (ee) of the product was 99.8% which was the same as the optical purity of the starting material. The optical purity was determined by chromatography on an analytical chiral column. [α]D 20=+129.9° (c=1%, methanol).
- (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H-benzimidazole sodium salt (0.165 g, 0.45 mmol) was dissolved in water (3 ml). To this mixture 2 ml of an aqueous solution of MgCl2xH2O (46 mg, 0.23 mmol) was added dropwise and the formed precipitate was isolated by centrifugation. There was obtained 85 mg (51%) of the product as a white powder. The optical purity (ee) of the product was 99.9% which was the same or better as the optical purity of the starting material. The optical purity was determined by chromatography on an analytical chiral column. [α]D 20=−128.2° (c=1%, methanol).
-
TABLE 1 Ex. Solvent NMR data δ ppm 1. DMSO-d6 2.20 (s, 3H), 2.22 (s, 3H), 3.69 (s, 3H), 3.72 (s, 3H), 500 MHz 4.37 (d, 1H), 4.75 (d, 1H), 6.54 (dd, 1H), 6.96 (d, 1H) 7.30 (d, 1H), 8.21 (s, 1H). 2. DMSO-d6 2.20 (s, 3H), 2.22 (s, 3H), 3.69 (s, 3H), 3.72 (s, 3H), 500 MHz 4.38 (d, 1H), 4.73 (d, 1H), 6.54 (dd, 1H), 6.96 (d, 1H), 7.31 (d, 1H), 8.21 (s, 1H). - A preferred method for preparing optically pure omeprazole enantiomer crystal salts of magnesium is described in Examples 6 and 7.
- Magnesium (0.11 g, 4.5 mmol) was dissolved and reacted with methanol (50 ml) at 40° C. with a catalytic amount of methylene chloride. The reaction was run under nitrogen and was finished after five hours. At room temperature a mixture of the two enantiomers [90% (−)-isomer and 10% (+)-isomer] of 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (2.84 g, 8.2 mmol) was added to the magnesium methoxide solution. The mixture was stirred for 12 hours whereupon a small amount of water (0.1 ml) was added in order to precipitate inorganic magnesium salts. After 30 minutes stirring, these inorganic salts were filtered off and the solution was concentrated on a rotavapor. The residue was now a concentrated methanolic solution of the enantiomeric mixture (i.e. the title compound contaminated with the (+)-isomer), with an optical purity (enantiomeric excess, e.e.) of 80%. This mixture was diluted with acetone (100 ml) and after stirring at room temperature for 15 minutes, a white precipitate was obtained. Additional stirring for 15 minutes and thereafter filtration afforded 1.3 g (50%) of the title compound as white crystals. Chiral analyses of the crystals and mother liquor were performed by chromatography on an analytical chiral column. The optical purity of the crystals and mother liquor was found to be 98.4 e.e. and 64.4% e.e., respectively. Thus, the optical purity (e.e.) has been enhanced from 80% to 98.4% simply by crystallizing the Mg-salt from a mixture of acetone and methanol. The product was crystalline as shown by powder X-ray diffraction and the magnesium content was 3.44% as shown by atomic absorption spectroscopy. [α]D 20=−131.5° (c=0.5%, methanol).
- Magnesium (0.11 g, 4.5 mmol) was dissolved and reacted with methanol (50 ml) at 40° C. with a catalytic amount of methylene chloride. The reaction was run under nitrogen and was finished after five hours. At room temperature a mixture of the two enantiomers [90% (+)-isomer and 10% (−)-isomer] of 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (2.84 g, 8.2 mmol) was added to the magnesium methoxide solution. The mixture was stirred for 12 hours whereupon a small amount of water (0.1 ml) was added in order to precipitate inorganic magnesium salts. After 30 minutes stirring, these inorganic salts were filtered off and the solution was concentrated on a rotavapor. The residue was now a concentrated methanolic solution of the enantiomeric mixture (i.e. the title compound contaminated with the (−)-isomer), with an optical purity (e.e.) of 80%. This mixture was diluted with acetone (100 ml) and after stirring at room temperature for one hour, a white precipitate was obtained. Additional stirring for 30 minutes and thereafter filtration afforded 0.35 g of the title compound as white crystals. Additional stirring of the mother liquor for 24 hours at room temperature afforded another 1.0 g (total yield=52%). Chiral analyses of the crystals and the second mother liquor were performed by chromatography on an analytical chiral column. The optical purity of the two crystal fractions was 98.8% e.e. and 99.5% e.e. respectively. The optical purity of the mother liquor was found to be 57% e.e. Thus, the optical purity (e.e.) has been enhanced from 80% to approximately 99% simply by crystallizing the Mg-salt from a mixture of acetone and methanol. The first precipitation was crystalline as shown by powder X-ray diffraction and the magnesium content of the same fraction was 3.49% as shown by atomic absorption spectroscopy. [α]D 20=+135.6° (c=0.5%, methanol).
- The crystalline salt according to Example 6 is most preferred.
- Preparation of the Synthetic Intermediates According to the Invention is Described in the following examples.
- A solution of 3.4 g sodium hydroxide in 40 ml water was added to a mixture of 14.4 g (42 mmol) tetrabutylammonium hydrogen sulfate and 6.4 g (42 mmol) (R)-(−)-mandelic acid. The mixture was extracted with 400 ml chloroform. After separation, the organic extract was heated to reflux with 16.6 g (42 mmol) of the racemate of 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1-[chloromethyl]-1H-benzimidazole. Evaporation of the solvent was followed by dilution with 100 ml dichloromethane and 700 ml ethyl acetate. The mixture was washed with 3×200 ml water and the organic solution was dried over MgSO4 and then evaporated. The crude material was purified by recrystallization from 100 ml acetonitrile, giving 8.1 g of the title compound (38%) as a diastereomeric mixture.
- NMR data are given below.
- The diastereomers of the title compound in Example 8 were separated using reversed phase chromatography (HPLC). Approximately 300 mg of the diastereomeric mixture was dissolved in 10 ml hot acetonitrile which was diluted with 10 ml of a mixture of aqueous 0.1 M ammoniumacetate and acetonitrile (70/30). The solution was injected to the column and the compounds were eluted with a mixture of aqueous 0.1 M ammoniumacetate and acetonitrile (70/30). The more hydrophilic isomer was easier to obtain pure than the less hydrophilic one. The work up procedure for the fraction which contained pure isomer was as follows; extraction with dichloromethane, washing the organic solution with aqueous 5% sodium hydrogen carbonate solution, drying over Na2SO4 and evaporation of the solvent on a rotavapor (at the end of the evaporation the removal of acetonitrile was facilitated by adding more dichloromethane). Using 1.2 g of the diastereomeric mixture with the above mentioned technique, the more hydrophilic isomer, 410 mg, was obtained in a pure state as a colorless syrup.
- NMR data are given below.
- The product was obtained from 8.1 g (202 mmol) sodium hydroxide in 100 ml water, 34.4 g (101 mmol) tetrabutylammonium hydrogen sulfate, 15.4 g (101 mmol) (S)-(+)-mandelic acid and 39.9 g (101 mmol) of the racemate of 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1-[chloromethyl]-1H-benzimidazole using the same procedure as in Example 8. Recrystallization from 100 ml acetonitrile yielded 21.3 g, i.e. 41% of the title compound as a diastereomeric mixture.
- NMR data are given below.
- The diastereomers of the title compound in Example 10 were separated using reversed phase chromatography (HPLC) in the same way as in Example 7, but using the diasteromeric mixture of 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-(R/S)-sulfinyl]-1-[(S)-mandeloloxymethyl]-1H-benzimidazole instead of the (R)-mandelic ester used in Example 9. Using 2.1 g of the diastereomeric mixture, the more hydrophilic isomer, 760 mg, was obtained in a pure state as a colorless syrup.
- NMR data are given below.
- 0.23 g (0.45 mmol) of the more hydrophilic diastereomer of 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1-[(R)-mandeloyloxymethyl]-1H-benzimidazole was dissolved in 15 ml methanol. A solution of 36 mg (0.9 mmol) sodium hydroxide in 0.45 ml water was added, and after 10 minutes the mixture was evaporated on a rotavapor. The residue was partitioned between 15 ml water and 15 ml dichloromethane. The organic solution was extracted with 15 ml water and to the combined aqueous solutions was added 85 μl (1.4 mmol) methyl formate. After 15 minutes the mixture was extracted with 3×10 ml dichloromethane. The organic solution was dried over Na2SO4 and then evaporated. There was obtained 0.12 g (77%) of the title compound as a colorless syrup. The optical purity (e.e.) which was analyzed by chiral column chromatography was 94%. [α]D 20=−155° (c=0.5%, chloroform).
- NMR data are given below
- 0.76 g (1.5 mmol) of the more hydrophilic diastereomer of 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1-[(S)-mandeloyloxymethyl]-1H-benzimidazole was dissolved in 50 ml methanol. A solution of 0.12 mg (3.0 mmol) sodium hydroxide in 1.5 ml water was added, and after 10 minutes the mixture was evaporated on a rotavapor. The residue was partitioned between 25 ml water and 25 ml dichloromethane. The organic solution was extracted with 25 ml water and to the combined aqueous solutions was added 200 μl (3.2 mmol) methyl formate. After 15 minutes the mixture was extracted with 3×25 ml dichloromethane. The organic solution was dried over Na2SO4 and then evaporated. There was obtained 0.42 g (81%) of the title compound as a colorless syrup. The optical purity (e.e.) which was analyzed by chiral column chromatography was 98%. [α]D 20=+157° (c=0.5%, chloroform).
- NMR data are given below
-
TABLE 2 Ex. Solvent NMR data δ ppm 8. CDCl3 2.18 (s, 3H), 2.20 (s, 3H), 2.36 (s, 3H), 2.39 (s, 3H), 500 MHz 3.77 (s, 3H), 3.78 (s, 3H), 3.82 (s, 3H), 3.87 (s, 3H), 4.80 (d, 1H), 4.88 (d, 1H), 5.0 (m, 2H), 5.34 (s, 2H), 6.43 (d, 1H), 6.54 (d, 1H), 6.6-6.7 (m, 2H), 6.90 (d, 1H), 6.95-6.98 (m, 2H), 7.01 (d, 1H), 7.2-7.3 (m, 6H), 7.37 (m, 2H), 7.44 (m, 2H), 7.58 (d, 1H), 7.62 (d, 1H), 7.95 (s, 1H), 7.97 (s, 1H). 9. CDCl3 2.20 (s, 3H), 2.36 (s, 3H), 3.78 (s, 3H), 3.82 (s, 3H), 500 MHz 4.80 (d, 1H), 5.00 (d, 1H), 5.35 (d, 1H), 6.43 (d, 1H), 6.63 (d, 1H), 6.90 (d, 1H), 6.97 (dd, 1H), 7.2-7.3 (m, 3H), 7.37 (m, 2H), 7.62 (d, 1H), 7.97 (s, 1H). 10. CDCl3 2.19 (s, 3H), 2.20 (s, 3H), 2.36 (s, 3H), 2.39 (s, 3H), 500 MHz 3.77 (s, 3H), 3.78 (s, 3H), 3.83 (s, 3H), 3.87 (s, 3H), 4.80 (d, 1H), 4.88 (d, 1H), 5.0 (m, 2H), 5.34 (s, 2H), 6.43 (d, 1H), 6.54 (d, 1H), 6.6-6.7 (m, 2H), 6.90 (d, 1H), 6.96-6.98 (m, 2H), 7.01 (d, 1H), 7.2-7.3 (m, 6H), 7.37 (m, 2H), 7.44 (m, 2H), 7.58 (d, 1H), 7.62 (d, 1H), 7.95 (s, 1H), 7.97 (s, 1H). 11. CDCl3 2.20 (s, 3H), 2.36 (s, 3H), 3.78 (s, 3H), 3.82 (s, 3H), 500 MHz 4.80 (d, 1H), 5.00 (d, 1H), 5.35 (d, 1H), 6.43 (d, 1H), 6.63 (d, 1H), 6.90 (d, 1H), 6.97 (dd, 1H), 7.2-7.3 (m, 3H), 7.37 (m, 2H), 7.62 (d, 1H), 7.97 (s, 1H). 12. CDCl3 2.18, (s, 3H), 2.22 (s, 3H), 3.68 (s, 3H), 3.83 (s, 3H), 300 MHz 4.77 (m, 2H), 6.93 (dd, 1H), ≈7.0 (b, 1H), ≈7.5 (b, 1H), 8.19 (s, 1H). 13. CDCl3 2.21 (s, 3H), 2.23 (s, 3H), 3.69 (s, 3H), 3.84 (s, 3H), 4.76 (m, 2H), 6.94 (dd, 1H), ≈7.0 (b, 1H), ≈7.5 (b, 1H), 8.20 (s, 1H). - Pharmaceutical preparations containing the compounds of the invention as active ingredient are illustrated in the following formulations.
- A syrup containing 1% (weight per volume) of active substance was prepared from the following ingredients:
-
Compound according to Example 1 1.0 g Sugar, powder 30.0 g Saccharine 0.6 g Glycerol 5.0 g Flavoring agent 0.05 g Ethanol 96% 5.0 g Distilled water q.s. to a final volume of 100 ml - Sugar and saccharine were dissolved in 60 g of warm water. After cooling the active compound was added to the sugar-solution and glycerol and a solution of flavoring agents dissolved in ethanol were added. The mixture was diluted with water to a final volume of 100 ml.
- An enteric coated tablet containing 50 mg of active compound was prepared from the following ingredients:
-
I Compound according to Example 6 500 g as Mg salt Lactose 700 g Methyl cellulose 6 g Polyvinylpyrrolidone cross-linked 50 g Magnesium stearate 15 g Sodium carbonate 6 g Distilled water q.s. II Cellulose acetate phthalate 200 g Cetyl alcohol 15 g Isopropanol 2000 g Methylene chloride 2000 g
I Compound according to Example 6, powder, was mixed with lactose and granulated with a water solution of methyl cellulose and sodium carbonate. The wet mass was forced through a sieve and the granulate dried in an oven. After drying the granulate was mixed with polyvinylpyrrolidone and magnesium stearate. The dry mixture was pressed into tablet cores (10 000 tablets), each tablet containing 50 mg of active substance, in a tabletting machine using 7 mm diameter punches.
II A solution of cellulose acetate phthalate and cetyl alcohol in isopropanol/methylene chloride was sprayed onto the tablets I in an Accela Cota®, Manesty coating equipment. A final tablet weight of 110 mg was obtained. - A parenteral formulation for intravenous use, containing 4 mg of active compound per ml, was prepared from the following ingredients:
-
Compound according to Example 2 4 g Sterile water to a final volume of 1000 ml - The active compound was dissolved in water to a final volume of 1000 ml. The solution was filtered through a 0.22 μm filter and immediately dispensed into 10 ml sterile ampoules. The ampoules were sealed.
- Capsules containing 30 mg of active compound were prepared from the following ingredients:
-
Compound according to Example 6 300 g Lactose 700 g Microcrystalline cellulose 40 g Hydroxypropyl cellulose low-substituted 62 g Disodium hydrogen phosphate 2 g Purified water q.s. - The active compound was mixed with the dry ingredients and granulated with a solution of disodium hydrogen phosphate. The wet mass was forced through an extruder and spheronized and dried in a fluidized bed dryer.
- 500 g of the pellets above were first coated with a solution of hydroxypropyl methylcellulose, 30 g, in water, 750 g, using a fluidized bed coater. After drying, the pellets were coated with a second coating as given below:
-
-
Hydroxypropyl methylcellulose phthalate 70 g Cetyl alcohol 4 g Acetone 200 g Ethanol 600 g - The final coated pellets were filled into capsules.
- Suppositories were prepared from the following ingredients using a welding procedure. Each suppository contained 40 mg of active compound.
-
Compound according to Example 1 4 g Witepsol H-15 180 g - The active compound was homogenously mixed with Witepsol H-15 at a temperature of 41° C. The molten mass was volume filled into pre-fabricated suppository packages to a net weight of 1.84 g. After cooling the packages were heat sealed. Each suppository contained 40 mg of active compound.
- The stability of the optically pure compounds of the invention against racemization has been measured at low concentrations in a refrigerator in aqueous buffer solutions at pH 8, 9.3, 10 and 11.2. The stereochemical stability was measured by comparing the optical purity for the (−)-isomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole in buffer solution immediately after dissolving and after several days. The measurement was performed by chromatography on an analytical chiral column. The surprising high stereochemical stability in alkaline conditions for the compounds of invention is exemplified by the fact that no racemization for the test compound was obtained at pH 11.2 even after 21 days. At pH 8, 9.3 and 10, the chemical degradation of the compound is more apparent which makes the racemization measurement more difficult to perform, however at none of these pH values a detectable racemization was obtained after 16 days.
- In another racemization experiment with the optically pure compounds of the invention, an aqueous phosphate buffer solution (pH=11) of the (+)-isomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt (c=10−5M) was warmed for 26 hours at 37° C. without any racemization at all being observed.
Claims (2)
1. An optically pure enantiomeric compound comprising a Na+, Mg2+, Li+, K+, Ca2+ or N+(R)4 salt of (+)-5-methoxy-2-[[(4-methoxy-3,5,dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or (−)-5-methoxy-2-[[(4-methoxy-3,5,dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, wherein R is an alkyl with 1-4 carbon atoms.
2-34. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/551,828 US20100222591A1 (en) | 1993-05-28 | 2009-09-01 | New Compounds |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE19939301830A SE9301830D0 (en) | 1993-05-28 | 1993-05-28 | NEW COMPOUNDS |
SE9301830-7 | 1993-05-28 | ||
US08/256,174 US5693818A (en) | 1993-05-28 | 1994-05-27 | Process for preparing pure salts of pyridinylmethyl-sulfinyl-1H-benzimidazole |
US08/376,512 US5714504A (en) | 1993-05-28 | 1995-01-23 | Compositions |
US89993197A | 1997-07-24 | 1997-07-24 | |
US18727798A | 1998-11-06 | 1998-11-06 | |
US09/690,044 US6875872B1 (en) | 1993-05-28 | 2000-10-16 | Compounds |
US11/002,982 US20060004057A1 (en) | 1993-05-28 | 2004-12-01 | New compounds |
US11/679,264 US20080312449A1 (en) | 1993-05-28 | 2007-02-27 | New Compounds |
US12/551,828 US20100222591A1 (en) | 1993-05-28 | 2009-09-01 | New Compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/679,264 Continuation US20080312449A1 (en) | 1993-05-28 | 2007-02-27 | New Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100222591A1 true US20100222591A1 (en) | 2010-09-02 |
Family
ID=20390088
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/256,174 Expired - Lifetime US5693818A (en) | 1993-05-28 | 1994-05-27 | Process for preparing pure salts of pyridinylmethyl-sulfinyl-1H-benzimidazole |
US08/376,512 Expired - Lifetime US5714504A (en) | 1993-05-28 | 1995-01-23 | Compositions |
US09/419,456 Expired - Lifetime US6143771A (en) | 1993-05-28 | 1999-10-15 | Compounds |
US11/679,264 Abandoned US20080312449A1 (en) | 1993-05-28 | 2007-02-27 | New Compounds |
US12/551,828 Abandoned US20100222591A1 (en) | 1993-05-28 | 2009-09-01 | New Compounds |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/256,174 Expired - Lifetime US5693818A (en) | 1993-05-28 | 1994-05-27 | Process for preparing pure salts of pyridinylmethyl-sulfinyl-1H-benzimidazole |
US08/376,512 Expired - Lifetime US5714504A (en) | 1993-05-28 | 1995-01-23 | Compositions |
US09/419,456 Expired - Lifetime US6143771A (en) | 1993-05-28 | 1999-10-15 | Compounds |
US11/679,264 Abandoned US20080312449A1 (en) | 1993-05-28 | 2007-02-27 | New Compounds |
Country Status (43)
Families Citing this family (208)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5877192A (en) * | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
US6875872B1 (en) | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
SE9301830D0 (en) * | 1993-05-28 | 1993-05-28 | Ab Astra | NEW COMPOUNDS |
SI1078628T1 (en) * | 1994-07-08 | 2009-04-30 | Astrazeneca Ab | Multiple unit tableted dosage form |
SE504459C2 (en) * | 1994-07-15 | 1997-02-17 | Astra Ab | Process for the preparation of substituted sulfoxides |
SE9500422D0 (en) * | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
SE9500478D0 (en) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
HRP960232A2 (en) * | 1995-07-03 | 1998-02-28 | Astra Ab | A process for the optical purification of compounds |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
SE9600070D0 (en) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
SE508669C2 (en) * | 1996-04-26 | 1998-10-26 | Astra Ab | New procedure |
SE510666C2 (en) * | 1996-12-20 | 1999-06-14 | Astra Ab | New Crystal Modifications |
SE9702000D0 (en) * | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
US6747155B2 (en) | 1997-05-30 | 2004-06-08 | Astrazeneca Ab | Process |
SE510650C2 (en) * | 1997-05-30 | 1999-06-14 | Astra Ab | New association |
SE510643C2 (en) * | 1997-06-27 | 1999-06-14 | Astra Ab | Thermodynamically stable omeprazole sodium form B |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
DK1037607T3 (en) * | 1997-12-08 | 2004-06-21 | Altana Pharma Ag | Newly known suppository form comprising an acid-labile active compound |
SE9704869D0 (en) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
SE9704870D0 (en) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
KR100627614B1 (en) * | 1998-04-20 | 2006-09-25 | 에자이 가부시키가이샤 | Medicament comprising stabilized compositions containing benzimidazole-type compounds |
BR9912937A (en) | 1998-08-10 | 2001-05-08 | Partnership Of Michael E Garst | Proton pump inhibitor prodrugs |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
SE9803772D0 (en) | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
JP4610086B2 (en) | 1998-11-18 | 2011-01-12 | アストラゼネカ・アクチエボラーグ | Improved chemical methods and pharmaceutical formulations |
SE9900274D0 (en) | 1999-01-28 | 1999-01-28 | Astra Ab | New compound |
US6852739B1 (en) * | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
TWI243672B (en) | 1999-06-01 | 2005-11-21 | Astrazeneca Ab | New use of compounds as antibacterial agents |
AU5871000A (en) * | 1999-06-11 | 2001-01-02 | Paul G. Abrams | High dose radionuclide complexes for bone marrow suppression |
US7094885B2 (en) * | 1999-07-11 | 2006-08-22 | Neorx Corporation | Skeletal-targeted radiation to treat bone-associated pathologies |
US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
EP1595879A3 (en) * | 1999-08-26 | 2010-01-27 | aaiPharma Inc. | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
JP2003510348A (en) * | 1999-10-01 | 2003-03-18 | ナトコ ファーマ リミテッド | IMPROVED PHARMACEUTICAL COMPOSITION AND PROCESS FOR PRODUCING THE SAME |
WO2001028559A1 (en) * | 1999-10-20 | 2001-04-26 | Eisai Co., Ltd. | Method for stabilizing benzimidazole compounds |
SE9903831D0 (en) | 1999-10-22 | 1999-10-22 | Astra Ab | Formulation of substituted benzimidazoles |
DE60015607T2 (en) | 2000-02-24 | 2005-11-10 | Kopran Research Laboratories Ltd. | ORAL ADMINISTRATIVE ACID-RESISTANT BENZIMIDAZOLE DERIVATIVES |
SE0000774D0 (en) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
US20030212274A1 (en) * | 2000-05-15 | 2003-11-13 | Bakthavathsalan Vijayaraghavan | Novel amorphous form of omeprazole salts |
US6306435B1 (en) * | 2000-06-26 | 2001-10-23 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same |
CA2386716C (en) * | 2002-05-17 | 2012-07-24 | Bernard Charles Sherman | Magnesium salt of s-omeprazole |
AU2003204233B8 (en) * | 2000-08-04 | 2008-06-26 | Bernard Charles Sherman | Magnesium salt of S-omeprazole |
US7271182B2 (en) | 2000-08-04 | 2007-09-18 | Takeda Pharmaceutical Company Limited | Salts of benzimidazole compound and use thereof |
US6544556B1 (en) | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
WO2002026210A2 (en) * | 2000-09-29 | 2002-04-04 | Geneva Pharmaceuticals Inc. | Proton pump inhibitor formulation |
JP2004536034A (en) | 2001-01-08 | 2004-12-02 | ネオルクス コーポレイション | Therapeutic and diagnostic compounds, compositions and methods |
US7064214B2 (en) * | 2001-04-13 | 2006-06-20 | Apsinterm Llc | Methods of preparing sulfinamides and sulfoxides |
SE0101379D0 (en) | 2001-04-18 | 2001-04-18 | Diabact Ab | Composition that inhibits gastric acid secretion |
US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
GB2376231A (en) | 2001-06-06 | 2002-12-11 | Cipla Ltd | Benzimidazole-cyclodextrin inclusion complex |
SE0102993D0 (en) | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
EP1428825A4 (en) | 2001-09-18 | 2005-03-23 | Zeria Pharm Co Ltd | Benzimidazole derivatives |
US20040006111A1 (en) * | 2002-01-25 | 2004-01-08 | Kenneth Widder | Transmucosal delivery of proton pump inhibitors |
ES2286408T3 (en) * | 2002-03-05 | 2007-12-01 | Astrazeneca Ab | SALES OF ALQUILAMONIO DE OMEPRAZOL E ESOMEPRAZOL. |
EP1492511B3 (en) | 2002-04-09 | 2012-05-02 | Flamel Technologies | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
US6894066B2 (en) * | 2002-05-09 | 2005-05-17 | Bernard Charles Sherman | Magnesium salt of S-omeprazole |
JP4463103B2 (en) * | 2002-07-19 | 2010-05-12 | ウィンストン・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー | Benzimidazole derivatives and their use as prodrugs of proton pump inhibitors |
TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
EP1534278A4 (en) * | 2002-08-01 | 2006-09-06 | Nitromed Inc | Nitrosated proton pump inhibitors, compositions and methods of use |
AU2003262992A1 (en) | 2002-08-30 | 2004-03-19 | Reddy's Laboratories Limited | Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof |
SE0203065D0 (en) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
ES2534713T3 (en) | 2002-10-16 | 2015-04-27 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
EP1556043A1 (en) * | 2002-10-22 | 2005-07-27 | Ranbaxy Laboratories, Ltd. | Amorphous form of esomeprazole salts |
WO2004046134A2 (en) * | 2002-11-18 | 2004-06-03 | Dr. Reddy's Laboratories Limited | Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation |
DE10254167A1 (en) | 2002-11-20 | 2004-06-09 | Icon Genetics Ag | Process for the control of cellular processes in plants |
RS52667B (en) | 2002-12-06 | 2013-06-28 | Nycomed Gmbh | Process for preparing optically pure active compounds |
AU2003293749B2 (en) | 2002-12-06 | 2009-12-24 | Takeda Gmbh | Process for preparing (S)-pantoprazole |
FR2848555B1 (en) | 2002-12-16 | 2006-07-28 | Negma Gild | ENANTIOMER (-) OF TENATOPRAZOLE AND ITS THERAPEUTIC APPLICATION |
WO2004066924A2 (en) * | 2003-01-24 | 2004-08-12 | Andrx Labs Llc | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
US20040248942A1 (en) * | 2003-02-20 | 2004-12-09 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
MXPA05009183A (en) * | 2003-02-28 | 2005-10-20 | Ranbaxy Lab Ltd | Polymorphs of s-omeprazole. |
WO2004089935A1 (en) * | 2003-04-10 | 2004-10-21 | Hetero Drugs Limitd | Novel crystalline forms of s-omeprazole magnesium |
CN1842525A (en) * | 2003-05-05 | 2006-10-04 | 兰贝克赛实验室有限公司 | Barium salt of benzimidazole derivative |
WO2004099182A1 (en) * | 2003-05-05 | 2004-11-18 | Ranbaxy Laboratories Limited | Zinc salt of (s)-omeprazole |
EP1644352A1 (en) * | 2003-07-15 | 2006-04-12 | Allergan, Inc. | Process for preparing isomerically pure prodrugs of proton pump inhibitors |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
TWI337877B (en) * | 2003-07-18 | 2011-03-01 | Santarus Inc | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
AR045062A1 (en) * | 2003-07-18 | 2005-10-12 | Santarus Inc | PHARMACEUTICAL FORMULATIONS TO INHIBIT THE SECRETION OF ACID AND METHODS TO PREPARE AND USE THEM |
PL1651217T3 (en) * | 2003-07-23 | 2008-07-31 | Nycomed Gmbh | Alkaline salts of proton pump inhibitors |
CN100457104C (en) * | 2003-07-23 | 2009-02-04 | 尼科梅德有限责任公司 | Alkaline salts of proton pump inhibitors |
WO2005011637A1 (en) * | 2003-08-04 | 2005-02-10 | Eisai Co., Ltd. | At-use dispersed preparation |
SE0302381D0 (en) | 2003-09-04 | 2003-09-04 | Astrazeneca Ab | New salts I |
SE0302382D0 (en) | 2003-09-04 | 2003-09-04 | Astrazeneca Ab | New salts II |
EP1663173A1 (en) * | 2003-09-25 | 2006-06-07 | Natco Pharma Limited | Enteric soft gelatin capsule containing esomeprazole and method of preparation |
MXPA06003450A (en) | 2003-09-26 | 2006-08-31 | Johnson & Johnson | Drug coating providing high drug loading and methods for providing the same. |
US20050075371A1 (en) * | 2003-10-03 | 2005-04-07 | Allergan, Inc. | Methods and compositions for the oral administration of prodrugs of proton pump inhibitors |
WO2005034924A1 (en) * | 2003-10-14 | 2005-04-21 | Natco Pharma Limited | Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation |
GB0403165D0 (en) * | 2004-02-12 | 2004-03-17 | Ct | Novel uses for proton pump inhibitors |
EP1715854A2 (en) * | 2004-02-18 | 2006-11-02 | Allergan, Inc. | Prodrugs for the intravenous administration of proton pump inhibitors |
AU2005216862A1 (en) * | 2004-02-18 | 2005-09-09 | Allergan, Inc. | Compositions comprising prodrugs of proton pump inhibitors |
SE0400410D0 (en) | 2004-02-20 | 2004-02-20 | Astrazeneca Ab | New compounds |
WO2005082888A1 (en) * | 2004-03-01 | 2005-09-09 | Milen Merkez Ilac Endustrisi A.S. | Process for the preparation of magnesium salt of omeprazole |
US7176319B2 (en) | 2004-04-28 | 2007-02-13 | Hetero Drugs Limited | Process for substituted sulfoxides |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US20050267157A1 (en) * | 2004-05-28 | 2005-12-01 | David White | Magnesium-S-omeprazole |
DK1748998T3 (en) | 2004-05-28 | 2010-05-10 | Hetero Drugs Ltd | New stereoselective synthesis of benzimidazole sulfoxides |
US20050267159A1 (en) * | 2004-05-28 | 2005-12-01 | Aaipharma, Inc. | Magnesium complexes of S-omeprazole |
US20080249134A1 (en) * | 2004-06-24 | 2008-10-09 | Ursula Hohlneicher | New Esomeprazole Sodium Salt Crystal Modification |
NZ551970A (en) * | 2004-06-24 | 2010-01-29 | Astrazeneca Ab | New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt |
US20060024362A1 (en) * | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
KR100847635B1 (en) * | 2004-08-06 | 2008-07-21 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Salts of Benzimidazole Derivative with Amines |
CN1993350B (en) | 2004-08-06 | 2010-05-12 | 卫材R&D管理有限公司 | Salt of benzimidazole derivative with amine, and process for producing the same |
US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
EP1830822A1 (en) * | 2004-12-24 | 2007-09-12 | LEK Pharmaceuticals D.D. | Stable pharmaceutical composition comprising an active substance in the form of solid solution |
US20060160783A1 (en) * | 2004-12-30 | 2006-07-20 | Transform Pharmaceuticals, Inc. | Novel omeprazole forms and related methods |
ES2259269B1 (en) | 2005-03-03 | 2007-11-01 | Esteve Quimica, S.A. | PROCEDURE FOR THE PREPARATION OF DERIVATIVES OF 2- (2-PIRIDILMETILSULFINIL) -BENCIMIDAZOL OPTICALLY ACTIVE. |
AU2006227032B2 (en) | 2005-03-25 | 2010-02-25 | Livzon Pharmaceutical Group Inc. | Substituted sulfoxide compounds, methods for preparing the same and use thereof |
RU2007145207A (en) * | 2005-05-06 | 2009-06-20 | Гленмарк Фармасьютикалз Лимитед (In) | ESOMEPRAZOL STRONGTED SALT, METHOD FOR PRODUCING IT AND CONTAINING ITS PHARMACEUTICAL COMPOSITIONS |
JP2008545627A (en) * | 2005-05-09 | 2008-12-18 | タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド | How to treat nephrolithiasis |
US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
US7803817B2 (en) | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
EP1891043A1 (en) | 2005-06-15 | 2008-02-27 | Hetero Drugs Limited | Amorphous esomeprazole hydrate |
KR100641534B1 (en) * | 2005-07-28 | 2006-11-01 | 한미약품 주식회사 | Process of esomeprazole and salts thereof |
CA2617248C (en) * | 2005-08-03 | 2015-09-29 | Tap Pharmaceutical Products, Inc. | Methods for treating hypertension |
US20070043085A1 (en) * | 2005-08-19 | 2007-02-22 | Glenmark Pharmaceuticals Limited | Process for the preparation of amorphous form of neutral esomeprazole |
WO2007031845A2 (en) * | 2005-09-14 | 2007-03-22 | Glenmark Pharmaceuticals Limited | Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation |
US7598273B2 (en) * | 2005-10-06 | 2009-10-06 | Auspex Pharmaceuticals, Inc | Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties |
US7576219B2 (en) * | 2005-10-26 | 2009-08-18 | Hanmi Pharm. Co., Ltd | Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same |
JP2009518394A (en) | 2005-12-05 | 2009-05-07 | アストラゼネカ・アクチエボラーグ | Novel process for the preparation of non-salt forms of esomeprazole |
EP1801110A1 (en) | 2005-12-22 | 2007-06-27 | KRKA, tovarna zdravil, d.d., Novo mesto | Esomeprazole arginine salt |
US7553857B2 (en) | 2005-12-23 | 2009-06-30 | Lek Pharmaceuticals D.D. | S-omeprazole magnesium |
EP1973896B1 (en) * | 2005-12-28 | 2009-04-15 | Union Quimico-Farmaceutica, S.A. | A process for the preparation of the (s)-enantiomer of omeprazole |
US8063074B2 (en) | 2006-05-04 | 2011-11-22 | Dr. Reddy's Laboratories Limited | Polymorphic forms of esomeprazole sodium |
ES2355164T3 (en) * | 2006-06-07 | 2011-03-23 | Astrazeneca Ab | NEW METHOD FOR THE PREPARATION OF ESOMEPRAZOL AMMONIUM SALTS. |
US7863330B2 (en) * | 2006-06-14 | 2011-01-04 | Rottapharm S.P.A. | Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders |
WO2008004245A1 (en) | 2006-07-05 | 2008-01-10 | Lupin Limited | Process for the preparation of optically pure or optically enriched enantiomers of sulphoxide compounds |
DK2046334T3 (en) | 2006-07-25 | 2014-08-25 | Vecta Ltd | Compositions and Methods to Inhibit Stomach Acid Secretion Using Derivatives of Small Dicarboxylic Acids in Combination with PPI |
WO2008036201A1 (en) * | 2006-09-19 | 2008-03-27 | Alevium Pharmaceuticals, Inc. | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety |
GB2444593B (en) | 2006-10-05 | 2010-06-09 | Santarus Inc | Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations |
US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
US20080103169A1 (en) | 2006-10-27 | 2008-05-01 | The Curators Of The University Of Missouri | Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same |
US20090124623A1 (en) * | 2006-11-13 | 2009-05-14 | Christopher Lademacher | Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors |
US20080269226A1 (en) * | 2006-11-13 | 2008-10-30 | Christopher Lademacher | Methods for Preserving Renal Function Using Xanthine Oxidoreductase Inhibitors |
EP1947099A1 (en) | 2007-01-18 | 2008-07-23 | LEK Pharmaceuticals D.D. | Process for solvent removal from omeprazole salts |
KR20090127870A (en) * | 2007-01-19 | 2009-12-14 | 다케다 파마슈티칼스 노쓰 어메리카, 인코포레이티드 | Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents |
EP2114919A2 (en) * | 2007-01-31 | 2009-11-11 | Krka Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic seperation |
US20080194307A1 (en) * | 2007-02-13 | 2008-08-14 | Jeff Sanger | Sports-based game of chance |
WO2008102145A2 (en) | 2007-02-21 | 2008-08-28 | Cipla Limited | Process for the preparation of esomeprazole magnesium dihydrate |
KR101303813B1 (en) * | 2007-04-16 | 2013-09-04 | 에스케이케미칼주식회사 | Improved preparing method of (S)-omeprazole from omeprazole racemate using optical resolution agent |
EP2000468A1 (en) * | 2007-05-09 | 2008-12-10 | Dr. Reddy's Laboratories Ltd. | Esomeprazole salts and processes for preparation thereof |
WO2008149204A1 (en) * | 2007-06-07 | 2008-12-11 | Aurobindo Pharma Limited | An improved process for preparing an optically active proton pump inhibitor |
CN101323609B (en) * | 2007-06-15 | 2013-05-01 | 成都福瑞生物工程有限公司 | Method for synthesizing high antipode content benzimidazole derivative by unsymmetrical oxidizing thioether into sulphoxide |
ES2375515T3 (en) | 2007-09-25 | 2012-03-01 | Hetero Drugs Limited | PREPARATION PROCEDURE FOR ESOMEPRAZOL ENANTIOMERICALLY PURE. |
EP2195309A4 (en) * | 2007-10-08 | 2013-04-24 | Hetero Drugs Ltd | Polymorphs of esomeprazole salts |
FR2925899B1 (en) * | 2007-12-27 | 2012-12-21 | Sidem Pharma Sa | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF SULFOXIDES. |
CN101980700A (en) | 2008-02-20 | 2011-02-23 | 密苏里大学董事会 | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
WO2009137648A1 (en) * | 2008-05-09 | 2009-11-12 | Aptapharma, Inc. | Multilayer proton pump inhibitor tablets |
US20090280173A1 (en) * | 2008-05-09 | 2009-11-12 | Ishwar Chauhan | Multilayer Omeprazole Tablets |
WO2009145368A1 (en) * | 2008-05-27 | 2009-12-03 | Sk Chemicals Co., Ltd. | Improved preparing method of (s)-omeprazole from omeprazole racemate using optical resolution agent |
EP2143722A1 (en) * | 2008-07-09 | 2010-01-13 | Lek Pharmaceuticals D.D. | Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium |
EP2147918A1 (en) | 2008-07-21 | 2010-01-27 | LEK Pharmaceuticals D.D. | Process for the preparation of S-omeprazole magnesium in a stable form |
KR20110079641A (en) | 2008-09-09 | 2011-07-07 | 아스트라제네카 아베 | Method for delivering a pharmaceutical composition to patient in need thereof |
EP2264024A1 (en) | 2008-10-14 | 2010-12-22 | LEK Pharmaceuticals d.d. | Process for the preparation of enantiomerically enriched proton pump inhibitors |
US8354541B2 (en) | 2008-11-18 | 2013-01-15 | Hetero Research Foundation | Optical purification of esomeprazole |
US20100311756A1 (en) * | 2009-01-22 | 2010-12-09 | Takeda Pharmaceuticals North America, Inc. | Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof |
WO2010097583A1 (en) | 2009-02-24 | 2010-09-02 | Cipla Limited | Esomeprazole potassium polymorph and its preparation |
US20110008432A1 (en) * | 2009-06-25 | 2011-01-13 | Pozen Inc. | Method for Treating a Patient in Need of Aspirin Therapy |
SG176724A1 (en) | 2009-06-25 | 2012-01-30 | Astrazeneca Ab | Method for treating a patient at risk for developing an nsaid-associated ulcer |
EP2319504A1 (en) | 2009-11-07 | 2011-05-11 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical solid dosage form |
WO2011058569A1 (en) | 2009-11-12 | 2011-05-19 | Hetero Research Foundation | Process for the resolution of omeprazole |
WO2011080500A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
WO2011080502A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
EP2519229A2 (en) | 2009-12-29 | 2012-11-07 | Novartis AG | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
EP2345408A3 (en) | 2010-01-08 | 2012-02-29 | Dr. Reddy's Laboratories Ltd. | Acid labile drug formulations |
JP5714031B2 (en) | 2010-02-12 | 2015-05-07 | エステヴェ キミカ, エス.エー. | Preparation method of sodium salt of esomeprazole sodium |
US20110207779A1 (en) * | 2010-02-25 | 2011-08-25 | Glenmark Generics Ltd | Process for the preparation of esomeprazole magnesium |
RU2013109380A (en) | 2010-09-10 | 2014-10-20 | Такеда Фармасьютикалс Ю.С.А.,Инк. | METHOD FOR RELATED THERAPY WITH APPLICATION OF THEOPHYLLINE AND FEBUKSOSTAT |
CN102816149B (en) * | 2011-06-10 | 2015-05-13 | 上海汇伦生命科技有限公司 | Preparation method for high-enantioselectivity synthesized (S)-omeprazole and salt thereof |
CN102807561A (en) * | 2011-06-21 | 2012-12-05 | 寿光富康制药有限公司 | S-omeprazole aluminum salt and preparation method and application thereof |
CN102850323A (en) * | 2011-06-30 | 2013-01-02 | 秦引林 | Refining method of esomeprazole sodium |
CN102321071B (en) * | 2011-07-20 | 2013-01-23 | 江苏奥赛康药业股份有限公司 | Industrial production method of high-purity esomeprazole sodium |
CN104844577A (en) * | 2011-07-31 | 2015-08-19 | 连云港润众制药有限公司 | Crystal forms of esomeprazole magnesium |
WO2013081566A1 (en) | 2011-11-25 | 2013-06-06 | Mahmut Bilgic | A formulation comprising benzimidazole |
EP2601947A1 (en) | 2011-12-05 | 2013-06-12 | Abo Bakr Mohammed Ali Al-Mehdar | Fixed-dose combination for treatment of helicobacter pylori associated diseases |
US20140328861A1 (en) | 2011-12-16 | 2014-11-06 | Atopix Therapeutics Limited | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis |
CA2860231A1 (en) | 2011-12-28 | 2013-07-04 | Pozen Inc. | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
WO2013108068A1 (en) | 2012-01-21 | 2013-07-25 | Jubilant Life Sciences Limited | Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers |
CN103420978A (en) * | 2012-05-15 | 2013-12-04 | 上海医药工业研究院 | Preparation method of magnesium salt of benzimidazole compound |
CN102657622A (en) * | 2012-05-17 | 2012-09-12 | 康普药业股份有限公司 | Preparation process of freeze-dry powder injection containing esomeprazole sodium |
CN102964335B (en) * | 2012-11-13 | 2014-06-25 | 凌元敏 | Esomeprazole sodium compound and preparation method and applications thereof |
CN103159737B (en) * | 2013-04-12 | 2014-03-19 | 四川省惠达药业有限公司 | Esomeprazole sodium compound and medicine composition |
WO2015065848A1 (en) | 2013-11-04 | 2015-05-07 | Capsugel Belgium Nv | Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole |
EP2929885A1 (en) | 2014-04-11 | 2015-10-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of rivaroxaban and proton pump inhibitors |
EP2933002A1 (en) | 2014-04-11 | 2015-10-21 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and proton pump inhibitors |
CN104045627A (en) * | 2014-05-21 | 2014-09-17 | 丽珠医药集团股份有限公司 | Purification method of omeprazole |
CN104530003A (en) * | 2014-06-10 | 2015-04-22 | 广东东阳光药业有限公司 | Preparation method of salts of pyridylmethyl sulfinyl-1H-benzimidazole compounds |
EP2980086B1 (en) | 2014-07-29 | 2016-06-15 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Efficient process for the preparation of esomeprazole (S)-binol complex |
EP3239146A4 (en) | 2014-12-26 | 2018-05-30 | The University of Tokyo | Method for producing proton pump inhibitor compound having optical activity |
ES2615637T3 (en) | 2015-03-06 | 2017-06-07 | F.I.S.- Fabbrica Italiana Sintetici S.P.A. | Improved procedure for optical purification of esomeprazole |
US10736855B2 (en) | 2016-02-25 | 2020-08-11 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
CN105924430A (en) * | 2016-06-27 | 2016-09-07 | 杭州富阳伟文环保科技有限公司 | Refinement method of esomeprazole sodium |
US10939686B2 (en) * | 2017-04-11 | 2021-03-09 | Mclaughlin Gormley King Company | Sabadilla oil and uses thereof |
CN108409714A (en) * | 2018-03-29 | 2018-08-17 | 成都通德药业有限公司 | The preparation method of esomeprazole, esomeprazole salt and esomeprazole magnesium |
CA3146660A1 (en) * | 2019-07-16 | 2021-01-21 | Kindred Biosciences, Inc. | Equine esomeprazole formulations and methods of use |
EP4015044A4 (en) | 2019-08-29 | 2022-10-19 | Tokyo University of Science Foundation | Method for preparing enantiomer of sulfoxide compound, and system for preparing enantiomer |
RU2726320C1 (en) * | 2020-02-09 | 2020-07-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Кемеровский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО КемГМУ) | Method for determining omeprazole impurity components |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4620008A (en) * | 1982-08-26 | 1986-10-28 | Aktiebolaget Hassle | Processes for the preparation of omeprazole and intermediates therefore |
US4636085A (en) * | 1982-03-16 | 1987-01-13 | Mapro Inc. | Apparatus for removing volatiles from plastic materials delivered to an extrusion or injection molding machine |
US4738974A (en) * | 1983-03-04 | 1988-04-19 | Aktiebolaget Hassle | Base addition salts of omeprazole |
US4758579A (en) * | 1984-06-16 | 1988-07-19 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Fluoroalkoxy substituted benzimidazoles useful as gastric acid secretion inhibitors |
US4786505A (en) * | 1986-04-30 | 1988-11-22 | Aktiebolaget Hassle | Pharmaceutical preparation for oral use |
US4853230A (en) * | 1986-04-30 | 1989-08-01 | Aktiebolaget Hassle | Pharmaceutical formulations of acid labile substances for oral use |
US5045321A (en) * | 1986-02-13 | 1991-09-03 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition and its production |
US5075323A (en) * | 1988-08-24 | 1991-12-24 | Aktiebolaget Hassle | Compounds including omeprazole in the treatment of glaucoma |
US5232706A (en) * | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
US5690960A (en) * | 1993-07-09 | 1997-11-25 | Astra Aktiebolag | Pharmaceutical formulation of omeprazole |
US5714504A (en) * | 1993-05-28 | 1998-02-03 | Astra Aktiebolag | Compositions |
US5817338A (en) * | 1994-07-08 | 1998-10-06 | Astra Aktiebolag | Multiple unit tableted dosage form of omeprazole |
US5877192A (en) * | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
US5888535A (en) * | 1993-04-27 | 1999-03-30 | Sepracor Inc. | Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole |
US5900424A (en) * | 1993-07-09 | 1999-05-04 | Astra Aktiebolag | Omeprazole magnesium salt form |
US5948789A (en) * | 1994-07-15 | 1999-09-07 | Astra Aktiebolag | Process for synthesis of substituted sulphoxides |
US6124464A (en) * | 1996-04-26 | 2000-09-26 | Astra Aktiebolag | Process for the preparation of a magnesium salt of a substituted sulfinyl heterocycle |
US6303788B1 (en) * | 1997-11-14 | 2001-10-16 | Astrazeneca Ab | Process for preparing omeprzole |
US6369085B1 (en) * | 1997-05-30 | 2002-04-09 | Astrazeneca Ab | Form of S-omeprazole |
US6511996B1 (en) * | 1999-01-28 | 2003-01-28 | Astrazeneca Ab | Potassium salt of (s)-omeprazole |
US6875872B1 (en) * | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7804231L (en) | 1978-04-14 | 1979-10-15 | Haessle Ab | Gastric acid secretion |
US4445708A (en) * | 1983-05-09 | 1984-05-01 | General Motors Corporation | Energy absorbing steering column for vehicles |
SE8403179D0 (en) * | 1984-06-13 | 1984-06-13 | Haessle Ab | NEW COMPOUNDS |
DE4035455A1 (en) * | 1990-11-08 | 1992-05-14 | Byk Gulden Lomberg Chem Fab | ENANTIOMER SEPARATION |
-
1993
- 1993-05-28 SE SE19939301830A patent/SE9301830D0/en unknown
-
1994
- 1994-05-06 IS IS4161A patent/IS1854B/en unknown
- 1994-05-11 TW TW083104255A patent/TW389761B/en not_active IP Right Cessation
- 1994-05-17 HR HR940307A patent/HRP940307B1/en active IP Right Review Request
- 1994-05-18 LT LTIP1941A patent/LT3287B/en not_active IP Right Cessation
- 1994-05-19 IL IL10968494A patent/IL109684A/en unknown
- 1994-05-23 ZA ZA943557A patent/ZA943557B/en unknown
- 1994-05-25 DZ DZ940055A patent/DZ1785A1/en active
- 1994-05-26 MA MA23521A patent/MA23210A1/en unknown
- 1994-05-27 PT PT94917244T patent/PT652872E/en unknown
- 1994-05-27 EP EP00108479A patent/EP1020460B1/en not_active Expired - Lifetime
- 1994-05-27 CA CA002139653A patent/CA2139653C/en not_active Expired - Lifetime
- 1994-05-27 DE DE69435220T patent/DE69435220D1/en not_active Expired - Lifetime
- 1994-05-27 JP JP50055395A patent/JP3549111B2/en not_active Expired - Lifetime
- 1994-05-27 RU RU95105587A patent/RU2137766C1/en active
- 1994-05-27 CA CA002337581A patent/CA2337581A1/en not_active Abandoned
- 1994-05-27 MY MYPI94001349A patent/MY121192A/en unknown
- 1994-05-27 DE DE0652872T patent/DE652872T1/en active Pending
- 1994-05-27 NZ NZ266915A patent/NZ266915A/en not_active IP Right Cessation
- 1994-05-27 SI SI9420002A patent/SI9420002B/en active Search and Examination
- 1994-05-27 PT PT00108480T patent/PT1020461E/en unknown
- 1994-05-27 SK SK101-95A patent/SK282524B6/en not_active IP Right Cessation
- 1994-05-27 EP EP94917244A patent/EP0652872B1/en not_active Revoked
- 1994-05-27 CN CN94190335A patent/CN1055469C/en not_active Expired - Lifetime
- 1994-05-27 YU YU31494A patent/YU49065B/en unknown
- 1994-05-27 DK DK00108479T patent/DK1020460T3/en active
- 1994-05-27 SG SG1996008770A patent/SG49283A1/en unknown
- 1994-05-27 US US08/256,174 patent/US5693818A/en not_active Expired - Lifetime
- 1994-05-27 EP EP00108480.5A patent/EP1020461B2/en not_active Expired - Lifetime
- 1994-05-27 AT AT94917244T patent/ATE197452T1/en not_active IP Right Cessation
- 1994-05-27 DK DK94917244T patent/DK0652872T3/en active
- 1994-05-27 PL PL94307261A patent/PL178994B1/en unknown
- 1994-05-27 TN TNTNSN94058A patent/TNSN94058A1/en unknown
- 1994-05-27 ES ES00108479T patent/ES2326404T3/en not_active Expired - Lifetime
- 1994-05-27 DE DE69435221T patent/DE69435221D1/en not_active Expired - Lifetime
- 1994-05-27 HU HU9500247A patent/HU226824B1/en active Protection Beyond IP Right Term
- 1994-05-27 ES ES00108480.5T patent/ES2326405T5/en not_active Expired - Lifetime
- 1994-05-27 DE DE69426254T patent/DE69426254T2/en not_active Revoked
- 1994-05-27 KR KR1019950700365A patent/KR100337274B1/en not_active IP Right Cessation
- 1994-05-27 PT PT00108479T patent/PT1020460E/en unknown
- 1994-05-27 WO PCT/SE1994/000509 patent/WO1994027988A1/en active IP Right Grant
- 1994-05-27 SI SI9420085A patent/SI22752B/en active Search and Examination
- 1994-05-27 DK DK00108480.5T patent/DK1020461T4/en active
- 1994-05-27 ES ES94917244T patent/ES2099047T3/en not_active Expired - Lifetime
- 1994-05-27 UA UA95018075A patent/UA60289C2/en unknown
- 1994-05-27 CZ CZ1995202A patent/CZ287876B6/en not_active IP Right Cessation
- 1994-06-04 SA SA94140756A patent/SA94140756B1/en unknown
- 1994-06-04 SA SA05260103A patent/SA05260103B1/en unknown
- 1994-11-17 EE EE9400363A patent/EE03157B1/en not_active IP Right Cessation
- 1994-12-30 LV LVP-94-266A patent/LV11034B/en unknown
-
1995
- 1995-01-23 US US08/376,512 patent/US5714504A/en not_active Expired - Lifetime
- 1995-01-24 NO NO950263A patent/NO307378B1/en not_active IP Right Cessation
- 1995-01-27 FI FI950377A patent/FI117755B/en active Protection Beyond IP Right Term
-
1997
- 1997-05-30 GR GR970300012T patent/GR970300012T1/en unknown
-
1998
- 1998-07-17 HK HK98109228A patent/HK1008330A1/en not_active IP Right Cessation
-
1999
- 1999-09-03 CN CN99118539A patent/CN1107503C/en not_active Expired - Lifetime
- 1999-10-15 US US09/419,456 patent/US6143771A/en not_active Expired - Lifetime
-
2000
- 2000-11-23 HK HK00107518.8A patent/HK1028044A1/en not_active IP Right Cessation
- 2000-11-23 HK HK00107520.4A patent/HK1028045A1/en not_active IP Right Cessation
-
2001
- 2001-02-05 GR GR20010400191T patent/GR3035365T3/en not_active IP Right Cessation
- 2001-05-22 CY CY0100010A patent/CY2224B1/en unknown
-
2003
- 2003-09-10 JP JP2003317637A patent/JP3959056B2/en not_active Expired - Lifetime
- 2003-09-10 JP JP2003317639A patent/JP4039999B2/en not_active Expired - Lifetime
-
2007
- 2007-01-02 FI FI20070002A patent/FI20070002A/en not_active Application Discontinuation
- 2007-02-27 US US11/679,264 patent/US20080312449A1/en not_active Abandoned
-
2009
- 2009-04-02 CL CL2009000805A patent/CL2009000805A1/en unknown
- 2009-09-01 US US12/551,828 patent/US20100222591A1/en not_active Abandoned
-
2011
- 2011-06-07 NO NO2011009C patent/NO2011009I1/en unknown
- 2011-09-19 LU LU91870C patent/LU91870I2/en unknown
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4636085A (en) * | 1982-03-16 | 1987-01-13 | Mapro Inc. | Apparatus for removing volatiles from plastic materials delivered to an extrusion or injection molding machine |
US4620008A (en) * | 1982-08-26 | 1986-10-28 | Aktiebolaget Hassle | Processes for the preparation of omeprazole and intermediates therefore |
US4738974A (en) * | 1983-03-04 | 1988-04-19 | Aktiebolaget Hassle | Base addition salts of omeprazole |
US4758579A (en) * | 1984-06-16 | 1988-07-19 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Fluoroalkoxy substituted benzimidazoles useful as gastric acid secretion inhibitors |
US5045321A (en) * | 1986-02-13 | 1991-09-03 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition and its production |
US4786505A (en) * | 1986-04-30 | 1988-11-22 | Aktiebolaget Hassle | Pharmaceutical preparation for oral use |
US4853230A (en) * | 1986-04-30 | 1989-08-01 | Aktiebolaget Hassle | Pharmaceutical formulations of acid labile substances for oral use |
US5075323A (en) * | 1988-08-24 | 1991-12-24 | Aktiebolaget Hassle | Compounds including omeprazole in the treatment of glaucoma |
US5232706A (en) * | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
US5888535A (en) * | 1993-04-27 | 1999-03-30 | Sepracor Inc. | Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole |
US5714504A (en) * | 1993-05-28 | 1998-02-03 | Astra Aktiebolag | Compositions |
US5877192A (en) * | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
US6875872B1 (en) * | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
US5690960A (en) * | 1993-07-09 | 1997-11-25 | Astra Aktiebolag | Pharmaceutical formulation of omeprazole |
US5900424A (en) * | 1993-07-09 | 1999-05-04 | Astra Aktiebolag | Omeprazole magnesium salt form |
US5817338A (en) * | 1994-07-08 | 1998-10-06 | Astra Aktiebolag | Multiple unit tableted dosage form of omeprazole |
US5948789A (en) * | 1994-07-15 | 1999-09-07 | Astra Aktiebolag | Process for synthesis of substituted sulphoxides |
US6124464A (en) * | 1996-04-26 | 2000-09-26 | Astra Aktiebolag | Process for the preparation of a magnesium salt of a substituted sulfinyl heterocycle |
US6369085B1 (en) * | 1997-05-30 | 2002-04-09 | Astrazeneca Ab | Form of S-omeprazole |
US6677455B2 (en) * | 1997-05-30 | 2004-01-13 | Astrazeneca Ab | Potassium salt of S-omeprazole |
US6303788B1 (en) * | 1997-11-14 | 2001-10-16 | Astrazeneca Ab | Process for preparing omeprzole |
US6511996B1 (en) * | 1999-01-28 | 2003-01-28 | Astrazeneca Ab | Potassium salt of (s)-omeprazole |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6143771A (en) | Compounds | |
US6875872B1 (en) | Compounds | |
EP0712401A1 (en) | Novel dialkoxy-pyridinyl-benzimidazole derivatives | |
AU676337C (en) | Optically pure salts of pyridinylmethyl sulfinyl-IH- benzimidazole compounds | |
WO1995032958A1 (en) | Novel substituted benzimidazoles | |
SK5896A3 (en) | Substituted benzimideazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |